Robert Negrin
Academic Appointments
- Professor, Medicine - Blood & Marrow Transplantation
- Member, Stanford Cancer Institute
Key Documents
Contact Information
-
Clinical Offices
Blood and Marrow Transplant Clinic 875 Blake Wilbur Dr Clinic E Stanford, CA 94305 Tel Work (650) 498-6000 Fax (650) 498-5030
- Academic Offices
Personal Information Email Tel (650) 723-0822Alternate Contact Sara Clark Tel Work 725-4959Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> Blood and Marrow Transplant
- Cancer> Hematology
- Blood and Marrow Transplantation
- Hematology
Administrative Appointments
- Medical Director, Clinical Bone Marrow Transplantation Laboratory (1990 - present)
- Division Chief, Blood and Marrow Transplant Program, Stanford University (2000 - present)
Honors and Awards
- Fellowship, Damon Runyon-Walter Winchell Cancer Fund (1988-1991)
- Fellow, Jose Carreras International Leukemia Foundation (1993-1996)
- President, International Society of Cellular Therapy (2000-2002)
- Distinguished Clinical Scientist Award, Doris Duke Foundation (2004-2009)
- President, American Society of Blood and Marrow Transplantation (2006-2007)
- Member, Association of American Physicians (AAP) (2008)
Professional Education
| Residency: | Stanford University School of Medicine CA (1987) |
| Internship: | Stanford University School of Medicine CA (1985) |
| Fellowship: | Stanford University School of Medicine CA (1987) |
| Board Certification: | Hematology, American Board of Internal Medicine (1992) |
| Board Certification: | Internal Medicine, American Board of Internal Medicine (1987) |
| Medical Education: | Harvard Medical School MA (1984) |
Postdoctoral Advisees
Maite Alvarez Rodriguez, Byung Su Kim, Everett Meyer, Hidekazu Nishikii, Antonio Pierini, Dominik Schneidawind
Graduate & Fellowship Program Affiliations
Community and International Work
- Volunteer, US
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
Research projects in our laboratory are aimed at studying the biology of cell populations capable of inducing or suppressing graft vs host disease as well as cells capable of promoting a graft vs tumor effect. In particular we are studying:
1) The clinical utility of expanded cytotoxic cells for immunotherapy. We have developed animal models utilizing mice with severe combined immunodeficiency (SCID) which will accept human tumor cells or murine model systems of syngeneic and allogeneic transplantation. In some instances the tumor cells are transfected with the bioluminescent marker luciferase so that the tumor cell growth can be quantitatively tracked in living animals. Using these model system we are studying the clinical efficacy of the expanded cytotoxic cells.
2) The interaction between the cytotoxic effector cells and a variety of tumor cell targets is under study. The role of granzyme/perforin and fas mediated pathways as well as the cell surface molecule NKG2D in cytotoxicity is under study.
3) We are exploring the biological impact of phenotypically defined populations of regulatory T cells on graft vs host disease and graft vs tumor reactions.
4) We are utilizing bioluminescent techniques to study these complex biological processes by either labelling the tumor or effector cell populations with the light emitting luciferase gene such that small numbers of cells can be tracked non-invasively, sensively and quantitatively.
Clinical Trials
- Recruiting TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD
- Recruiting Phase I/II of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
- Not Recruiting Transplantation for Patients With Chronic Lymphocytic Leukemia
- Recruiting Allogeneic Transplantation Using TL1 & ATG for Older Patients With Hematologic Malignancies
- Recruiting Double Cord Versus Haploidentical (Blood and Marrow Transplant Clinical Trials Network #1101)
Publications
- A distinct evolution of the T cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease. Blood. 2013
- Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity. Proc Natl Acad Sci U S A. 2012; (15): 5820-5
- Long-term outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and transplantation of purified autologous hematopoietic stem cells. Biol Blood Marrow Transplant. 2012; (1): 125-33
- Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood. 2012; (25): 6145-54
- Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells. Blood. 2012; (24): 5758-68
- Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. Bone Marrow Transplant. 2012; (4): 581-8
Help